Antibody engineering at the millennium

BioTechniques

Volumn 29, Issue 1, 2000, Pages 128-145

  Gavilondo, Jorge V ^a   Larrick, James W ^b  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Palo Alto Institute of Molecular Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PRODUCTION; GENETIC ENGINEERING; HUMAN; IMMUNOTHERAPY; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW;

EID: 0033922560     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/00291ov01     Document Type: Review

References (169)

1. Adams, G.P. and R. Schier. 1999. Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 237:249-260.
2. Ames, R.S., MA. Tornetta, K. Deen, C.S. Jones, A.M. Swift and S. Ganguly. 1995. Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins. J. Immunol. Methods 184:177-186.
3. Ayala, M., M. Dueñas, A. Santos, J. Vazquez, A. Menéndez, A. Silva and J.V. Gavilondo. 1992. Bacterial single chain antibody fragments, specific for carcinoembryonic antigen. BioTechniques 13:790-799.
4. Ayala, M., M.E. Fernández-de-Cossío, L. Canaán-Haden, R.F. Balint, J.W. Larrick and J.V. Gavilondo. 1995. Variable region sequence modulates periplasmic export of a single chain Fv antibody fragment in E. coli. BioTechniques 18:832-842.
5. Barbas, III, C.F., A.S. Kang, R.A. Lerner and S.J. Benkovic. 1991. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc. Natl. Acad. Sci. USA 88:7978-7982.
6. Barbas, C.F., III, and R.A. Lerner. 1991. Combinatorial immunoglobulin libraries on the surface of phage (Phabs): rapid selection of antigen specific Fabs. Methods: A Companion to Methods Enzymol. 2:119-124.
7. Barbas, III, C.F., J.D. Bain, D.M. Hoekstra and R.A. Lerner. 1992. Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA 89:4457-4461.
8. Barbas, III, C.F., D. Hu, N. Dunlop, L. Sawyer, D. Cababa, R.M. Hendry, P.L. Nara and D.R. Burton. 1994. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross reactivity. Proc. Natl. Acad. Sci. USA 91: 3809-3813.
9. Bebbington, C.R., G. Renner, S. Thomson, D. King, D. Abrams and G.T. Yarranton. 1992. High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 10:169-175.
10. Better, M., C.P. Chang, R.R. Robinson and A.H. Horwitz. 1988. Escherichia coli secretion of an active chimeric antibody fragment. Science 240:1041-1043.
11. Bird, R.E., K.D. Hardman, J.W. Jacobson, S. Johnson, B.M. Kaufman, S.-M. Lee, T. Lee, S.H. Pope, G.S. Riordan and M. Whitlow. 1988. Single chain antigen binding proteins. Science 242:423-426.
12. Borrebaeck, C.A.K. 1989. Strategy for the production of human monoclonal antibodies using in vitro activated B cells. J. Immunol. Methods 123:157-165.
13. Borrebaeck, C.A.K. (Ed.) 1995. Antibody Engineering. Oxford University Press. New York.
14. Borrebaeck C.A.K. 1999. Human monoclonal antibodies: the emperor's new clothes? Nat. Biotechnol. 17:821.
15. Boulianne, G.L., N. Hozumi and M.J. Shulman. 1984. Production of functional chimeric mouse/human antibodies. Nature 312:643-646.
16. Buchner, J. and R. Rudolph. 1991. Renaturation, purification, and characterization of recombinant Fab-fragments produced in Escherichia coli. Bio/Technology 9:157-161.
17. Butler, D. 1999. IBM promises scientists 500-fold leap in supercomputing power. Nature 402:705-706.
18. Cabilly, S., A.D. Riggs, H. Pande, J.E. Shively, W.E. Holmes, M. Rey, L.J. Perry, R. Wetzel and H.L. Heyneker. 1984. Generation of antibody activity from immunoglobulin polypeptide chains produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 81:3273-3277.
19. Canaán-Haden, L., M. Ayala, M.E. Fernández-de-Cossio, I. Pedroso, L. Rodés and J.V. Gavilondo. 1995. Purification and application of a single chain Fv antibody fragment specific to hepatitis B virus surface antigen. BioTechniques 19:606-614.
20. Caroll, W.L., K. Thielemans, J. Dilley and R. Levy. 1986. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89:61-72.
21. Caroll, W.L., E. Mendel and S. Levy. 1988. Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol. Immunol. 25:991-995.
22. Carr, F.J., G. Carter and A. Hamilton. 2000 (issued). Method for the production of non-immunogenic proteins. EP 983303A1.
23. Carter, P., R.F. Kelley, M.L. Rodrigues, B. Snedecor, M. Covarrubias, M.D. Velligan, W.-L.T. Wong, A.M. Rowland et al. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10:163-167.
24. Casadevall, A. and M.D. Scharff. 1995. Return to the past: the case for antibody based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161.
25. Casadevall, A. 1996. Antibody-based therapies for emerging infectious diseases. Emerg. Infect. Dis. 2:200-208.
26. Casalvilla, R., M. Dueñas, M. Ayala, S. Cruz, L. Cruz, W.A. Buurman and J.V. Gavilondo. 1999. A bacterial single-chain Fv antibody fragment that inhibits binding of its parental anti-E selectin monoclonal antibody to activated human endothelial cells. J. Biotechnol. 72:1-12.
27. Cavaillon, J.-M. 1994. Controversies surrounding current therapies for sepsis syndrome. Bull. Inst. Pasteur 93:21-41.
28. Chamov, S.M. and A. Ashkenazi. 1996. Immunoadhesins: principles and applications. TIBTECH 14:52-59.
29. Chaudhary, V.K., J.K. Batra, M.G. Gallo, M.C. Willingham, D.J. Fitzgerald and I. Pastan. 1990. A rapid method of cloning functional variable region antibody genes in Escherichia coli as single-chain immunotoxins. Proc. Natl. Acad. Sci. USA 37:1066-1070.
30. Chiswell, D.J. and J. McCafferty. 1992. Phage antibodies: will new coliclonal antibodies replace monoclonal antibodies? TIBTECH 10:80-84.
31. Clackson, T. and J.A. Wells. 1994. In vitro selection from protein and peptide libraries. TIBTECH 12:173-184.
32. Colcher, D., G. Pvlinkova, G. Beresford, B.J.M. Booth, A. Choudhury and S.K. Batra. 1998. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nuclear Med. 42:225-241.
33. Dall'Acqua, W. and P. Carter. 1998. Antibody Engineering. Curr. Opin. Oncol. 10:548-551.
34. Daugherty, P.S., G. Chen, M.J. Olsen, B.L. Iverson and G. Georgiou. 1998. Antobody affinity maturation using bacterial surface display. Protein Eng. 11:825-832.
35. Davis, G.T., W.D. Bedzyk, E.W. Voss and T.W. Jacobs. 1991. Single chain antibody (SCA) encoding genes: one-step construction and expression in eukaryotic cells. Bio/Technology 9:165-169.
36. de Haard, H., P. Henderikx and H.R. Hoogenboom. 1998. Creating and engineering human antibodies for immunotherapy. Adv. Drug Delivery Rev. 31:5-31.
37. de Haard, H.J., N. van Neer, A. Reurs, S.E. Hufton, R.C. Roovers, P. Henderikx, A.P. de Bruine, J.-W. Arends and H.R. Hoogenboom. 1999. A large non-immunized human Fab fragment phage library that permits isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274:18118-18230.
38. Delagrave, S., J. Catalan, C. Sweet, G. Drabik, A. Henry, A. Rees, T.P. Monath and F. Guirakhoo. 1999. Effects of humanization by variable domain resurfacing on the antiviral activity of a single-chain antibody against respiratory syncytial virus. Protein Eng. 12:357-362.
39. Dickman, S. 1998. Antibodies stage a comeback in cancer treatment. Science 280:1196-1197.
40. Dueñas, M. and C.A.K. Borrebaeck. 1994. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Bio/Technology 12:999-1002.
41. Duenas, M., J. Vázquez, M. Ayala, E. Soderlind, M. Ohlin, L. Pérez, C.A.K. Borrebaeck and J.V. Gavilondo. 1994. Intraand extracellular expression of a scFv antibody fragment in E. coli: effect of bacterial strains and pathway engineering using Gro-ES/L chaperonins. BioTechniques 16:476-483.
42. Dueñas, M., M. Ayala, J. Vázquez, M. Ohlin, E. Soderlind, C.A.K. Borrebaeck and J. Gavilondo. 1995. A point mutation in a murine immunoglobulin V-region strongly influences the antibody yield in Escherichia coli. Gene 158:61-66.
43. Dueñas, M., L.-T. Chin, A.C. Malmborg, R. Casalvilla, M. Ohlin and C.A.K. Borrebaeck. 1996. In vitro immunization of naïve B cells yields high affinity human IgG antibodies as illustrated by phage display. Immunology 89:1-7.
44. Dueñas, M. and J.C. Almagro. 1997. Construction and selection of scFv antibody fragments from restricted human libraries. Short Report. Advances in Modern Biotechnology Vol IV. Proceedings of the International Congress Biotecnología Habana'97. Elfos Scientiae. La Habana, Cuba. December 1-6. pp. R8.
45. Dunham, I., N. Shimizu, B.A. Roe, S. Chissoe, A.R. Hunt, J.E. Collins, R. Bruskiewich, D.M. Beare et al. 1999. The DNA sequence of human chromosome 22. Nature 402:489-495.
46. Ekberg, H., L. Backman, G. Tufveson and G. Tyden. 1999. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transplant. Proc. 31: 267-268.
47. Eldin, P., M.E. Pauza, Y. Hieda, G. Lin, M.P. Murtaugh, P.R. Pentel and C.A. Pennell. 1997. High level secretion of two antibody single chain Fv fragments by Pichia pastoris. J. Immunol. Methods 201:67-75.
48. Emery, S.C. and W.J. Harris. 1995. Strategies for humanizing antibodies. p. 159-183. In C.A.K. Borrebaeck (Ed.), Antibody Engineering. Oxford University Press, New York.
49. Farah, R.A., B. Clinchy, L. Herrera and E.S. Vitetta. 1998. The development of monoclonal antibodies for the therapy of cancer. Gene Expr. 8:321-345.
50. Ferguson, M., P.D. Minor, A.J. Garret, M. Page, R. Thorpe and T. Barrowclifie. 1996. Testing plasma pools for markers of viral contamination: the UK experience. Vox Sang. 77:21-26.
51. Fiedler, U. and U. Conrad. 1995. High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. Bio/Technology 13:1090-1093.
52. Freyre, F.M., J.E. Vázquez, M. Ayala, L. Canaán-Haden, H. Bell, I. Rodríguez, A. González, A. Cintado and J.V. Gavilondo. High level expression of an anti-CEA single chain Fv antibody fragment in the methylotrophic yeast Pichia pastoris. J. Biotechnol. (In Press).
53. Gillies, S.D., S.L. Morrison, V.T. Oi and S. Tonegawa. 1983 A tissue-specific transcription enhancer element is located in the major intron of rearranged immunoglobulin heavy chain gene. Cell 33:717-729.
54. Glaser, V. 1996. Can ReoPro repolish tarnished monoclonal therapeutics? Nat. Biotechnol. 14:1216-1217.
55. Glockshuber, R., M. Malia, I. Pfitzinger and A. Plückthun. 1990. A comparison of strategies to stabilize immunoglobulin Fv fragments. Biochemistry 29:1362-1367.
56. Green, L.L. 1999. Antibody engineering via genetic engineering of the mouse: Xeno-Mouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods 231:11-23.
57. Greenman, J., E. Jones, M.D. Wright and A.N. Barclay. 1996. The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface molecules. J. Immunol. Methods 194:169-180.
58. Griffiths, A.D., S.C. Williams, O. Hartley, I.M. Tomlinson, P. Waterhouse, W.L. Crosby, R.E. Kontermann, P.T. Jones et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:3245-3260.
59. Grillo-Lopez, A.J., C.A. White, C. Varns, D. Shen, A. Wei, A. McClure and B.K. Dallaire. 1999. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin. Oncol. 26:66-73.
60. Grunow, R., S. Jahn, T. Porstmann, S.S. Kiessig, H. Steinkellner, F. Steindl, D. Mattanovich, L. Gurtler et al. 1988. The high efficiency human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J. Immunol. Methods 106:257-265.
61. Hanes, J. and A. Plückthun. 1997. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA 94:4937-4942.
62. Hanes, J., L. Jermutus, C. Schaffitzel and A. Plückthun. 1999. Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems. FEBS Lett. 450:105-110.
63. Harvill, E.T., J.M. Fleming and S.L. Morrison. 1996 In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation. J. Immunol. 157: 3165-3170.
64. He, M. and M.J. Taussig. 1997. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res. 25:5132-5134.
65. He, M., M. Menges, M.A. Groves, E. Corps, H. Liu, M. Bruggemann and M.J. Taussig. 1999. Selection of a human antiprogesterone antibody fragment from a transgenic mouse library by ARM ribosome display. J. Immunol. Methods 231:105-117.
66. Hendricks, M.B., C.A. Luchette and M.J. Banker. 1989. Enhanced expression of an immunoglobulin-based vector in myeloma cells mediated by co-amplification with a mutant dihydrofolate reductase gene. Bio/Technology 7:1271-1274.
67. Hendy, S., Z.C. Chen, H. Barker, S. Santa Cruz, S. Chapman, L. Torrance, W. Cockburn and G.C. Whitelam. 1999. Rapid production of single-chain Fv fragments in plants using a potato virus X episomal vector. J. Immunol. Methods 231:137-146.
68. Hiatt, A., R. Cafferkey and K. Bowdish. 1989. Production of antibodies in transgenic plants. Nature 342:76-87.
69. Hoess, A, J. Wolle, L. Ge, P. Pack, P. Kufer and A. Knappik. 1997. Generation of human antibodies that selectively recognize diseased cells overexpressing surface bound antigens. Proc. Annu. Meet. Am. Assoc. Cancer Res. 38:A198.
70. Hogrefe, H., R. Mullinax, A. Lovejoy, B. Hay and J. Sorge. 1993. A bacteriophage veclor for the cloning and expression of immunoglobulin Fab fragments on the surface of filamentous phage. Gene 128:119-126.
71. Hoogenboom, H., A. Griffiths, K. Johnson, D. Chiswell, P. Hudson and G. Winter. 1991. Multisubunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res. 79:4133-4137.
72. Horwitz, A.H., C.P. Chang, M. Better, K.E. Hellstrom and R.R. Robinson. 1988 Secretion of functional antibody and Fab fragments from yeast cells. Proc. Natl. Acad. Sci. USA 85:8678-8682.
73. Hudson, P.J. 1999. Recombinant antibody constructs in cancer therapy. Curr. Opin. Immunol. 11:548-557.
74. Hudson, P.J. and A.A. Kortt. 1999. High avidity scFv multimers: diabodies and triabodies. J. Immunol. Methods 231:177-189.
75. Huennekens, F.M. 1994. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. TIBTECH 12:234-238.
76. Huston, J.S., D. Levinson, M. Mudgett-Hunter, M. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E, Bruccoleri et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single chain Fv analoque produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-5883.
77. Huston, J.S., M. Mudgett-Hunter, M.S. Tai, J. McCartney, F. Warren, E. Haber and H. Oppermann. 1991. Protein engineering of single-chain Fv analogs and fusion proteins. Meth. Enzymol. 203:46-88.
78. Huston, J. 1993. Medical applications of single-chain antibodies. Int. Rev. Immunol. 10:195-217.
79. Jardieu, P.M. and R.B. Fick, Jr. 1999. IgE inhibition as a therapy for allergic disease. Int. Arch. Allergy Immunol. 118:112-115.
80. Jung, S., K.M. Arndt, K.M. Muller and A. Plückthun. 1999. Selectively infective phage (SIP) technology: scope and limitations. J. Immunol. Methods 231:93-104.
81. Rabat, E., T.E. Wu, H. Perry, K.S. Gottesman smd C. Foeller. 1991. Sequences of Proteins of Immunological Interest. US Department of Health and Human Services. Public Health Service. NIH Publication No. 91-3242.
82. Kairemo, K.J.A. 1996. Radioimmunotherapy of solid cancers. Acta Oncol. 35:343-355.
83. Kettleborough, C.A., J. Saldanha, K.H. Ansell and M.M. Bendig. 1993. Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction. Eur. J. Immunol. 23:206-211.
84. Khazaeli, M.B., R.M. Conry and A.F. LoBuglio. 1994. Human immune response to monoclonal antibodies. J. Immunother. 15:42-52.
85. Kieke, M.C., E.V. Shusta, E.T. Boder, L. Teyton, K.D. Wittrup and D.M. Kranz. 1999. Selection of functional T cell receptor mutants from a yeast surface-display library. Proc. Natl. Acad. Sci. USA 96:5651-5656.
86. Kipriyanov, S.M., S. Dubel, F. Breitling, R.E. Kontermann, S. Heyman and M. Little. 1995. Bacterial expression and refolding of single chain Fv fragments with C-terminal cysteines. Cell Biophys. 26:187-204.
87. Knappik, A. and A. Plückthun. 1995. Engineered turns of an antibody improve its in vivo folding. Protein Eng. 8:81-89.
88. Knappik, A. 1997. Recombinant human antibodies which can be routinely optimized. "Antibody Therapeutic Antibodies '97", Larrick, J.W., Burton, D. (org.), San Francisco, California, September 21-24.
89. Köhler, G. and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:52-53.
90. Kotula, L. and P.J. Curtis. 1991. Evaluation of foreign gene codon optimization in yeast: expression of a mouse Ig kappa chain. Bio/Technology 9:1386-1389.
91. Kreitman, R.J., W.H. Wilson, D. Robbins, I. Margulies, M. Stetler-Stevenson, T.A. Waldmann and I. Pastan. 1999. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94:3340-3348.
92. Kretzschmar, T., L. Aoustin, O. Zingel, M. Marangi, B. Vonach, H. Towbin and M. Geiser. 1996. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J. Immunol. Methody 195:93-101.
93. Larrick, J.W., Y.L. Chiang, R. Sheng-Dong, G. Senck and P. Casali. 1988. Generation of specific human monoclonal antibod-ies by in vitro expansion of human B-cells: a novel recombinant DNA approach. p. 231-246. In C.A.K. Borrebaeck (Ed.), In Vitro Immunization and Hybridoma Technology. Elsevier Science, Amsterdam.
94. Larrick, J.W., L. Danielsson, C.A. Brenner, M. Abrahamson, K.E. Fry and C.A.K. Borrebaeck. 1989. Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem. Biophys. Res. Commun. 160:1250-1256.
95. Larrick, J.W., L. Yu, J. Chen, S. Jaiswal 144 BioTechniques and K. Wycoff. 1998. Production of antibodies in transgenic plants. Res. Immunol. 149:603-608.
96. Levy, R. and R. Miller. 1983. Biological and clinical implications of hybridomas: tumor therapy with monoclonal antibodies. Annu. Rev. Med. 14:1352-1359.
97. Lilley, G., O. Dolezal, C.J. Hillyard, C. Bernard and P.J. Hudson. 1994. Recombinant single-chain antibody peptide conjugates expressed in Escherichia coli for the rapid diagnosis of HIV. J. Immunol. Methods 177:211-226.
98. Little, M., M. Welschof, M. Braunagel, I. Hermes, C. Christ, A. Keller, P. Rohrbach, T. Kurschner et al. 1999. Generation of a large complex antibody library from multiple donors. J. Immunol. Methods 231:3-9.
99. Lunde, E., L.A. Munthe, A. Vabo, I. Sandlie and B. Bogen. 1999. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat. Biotechnol. 17:670-675.
100. Maini, R., E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery et al. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrex-ate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939.
101. Marasco, W.A., J. LaVecchio and A. Winkler. 1999. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods 231:223-238.
102. Marks, J.D., A.D. Griffiths, M. Malqvist, T.P. Clackson, J.M. Bye and G. Winter. 1992. By-passing immunization: building high affinity human antibodies by chain shuffling. Bio/Technology 10:779-783.
103. Mateo, C., E. Moreno, K. Amour, J. Lombardero, W. Harris and R. Pérez. 1997. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotecnol. 3:71-81.
104. Maurer Reiter, Y. and I. Pastan. 1998. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 18:513-520.
105. Mayer, A., K.A. Chester, A.A. Flynn and R.H. Begent. 1999. Taking engineered antiCEA antibodies to the clinic. J. Immunol. Methods 257:261-273.
106. McCafferty, J., A.D. Griffiths, G. Winter and D. Chiswell. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554.
107. McCafferty, J. and K.S. Johnson. 1996. Construction and screening of antibody display libraries. Phage Display of Peptides and Proteins. Academic Press, San Diego.
108. Melani, C., M. Figini, D. Nicosia, E. Luison, V. Ramakrishna, G. Casorati, G. Parmiani, Z. Eshhar, S. Canevari and M.P. Colombo. 1998. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res. 58:4146-4154.
109. Mendez, M.J., L.L. Gree, J.R.F. Corvalan, X.-C. Jia, C.E, Maynard-Currie, X.-D. Yang, M.L. Gallo, D.M. Louie et al. 1997 Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet. 15:146-156.
110. Milgrom, H., R.B. Fick, Jr, J.Q. Su, J.D. Reimann, R.K. Bush, M.L. Watrous and W.J. Metzger. 1999. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341:1966-1973.
111. Molloy, P.E., W.J. Harris, G. Strachan, C. Watts and C.P. Cunningham. 1998. Production of soluble single-chain T-cell receptor fragments in Escherichia coli trxB mutants. Mol. Immunol. 35:273-281.
112. Morrison, S.L., M.J. Johnson, L.A. Herzenberg and V.T. Oi. 1984. Chimaeric human antibody molecules: mouse antigen binding domains. Proc. Natl. Acad. Sci. USA 82: 6851-6855.
113. Morrison, S.L. 1985. Transfectomas provide novel chimeric antibodies. Science 229:1202-1207.
114. Mullis, K.B., F. Faloona, S. Scharf, R. Saiki, G. Horn and H. Erlich. 1986. Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring Harb. Symp. Quant. Biol. 1:263-273.
115. Mulloy, L.L., F. Wright, M.L. Hall and M. Moore. 1999. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplant. Proc. 31:1210-1213.
116. Neuberger, M.S. 1983. Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells. EMBO J. 2:1373-1378.
117. Neuberger, M.S., G.T. Williams and R.O. Fox. 1984. Recombinant antibodies possessing novel effector functions. Nature 312:604-608.
118. Neuberger, M. and M. Gruggermann. 1997. Monoclonal antibodies. Mice perform a human repertoire. Nature 386:25-26.
119. Nissim, A., H.R. Hoogenboom, I.M. Tomlinson, G. Flynn, C. Midgely, D. Lane and G. Winter. 1994. Antibody fragments from single pot phage display library as immunochemical reagents. EMBO J. 13:692-698.
120. Nyyssonen, E., M. Penttila, A. Harkki, A. Saloheimo, J.K.C. Knowles and S. Keranen. 1993. Efficient production of antibody fragments by the filamentous fungus Trichoderma reseei. Bio/Technology 11:591-595.
121. Ohage, E.C., P. Wirtz, J. Barnikow and B. Steipe. 1999. Intrabody construction and expression. II. A synthetic catalytic Fv fragment. J. Mol. Biol. 291:1129-1134.
122. Oi, V.T., S.L. Morrison, L.A. Herzenberg and P. Berg. 1983. Immunoglobulin gene expression in transformed lymphoid cells. Proc. Natl. Acad. Sci. USA 80:825-829.
123. Orlandi, R., D.H. Gussow, P.T. Jones and G. Winter. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-3837.
124. Pack, P., M. Kujau, M., Schroeckh, U. Knupfer, R. Wenderoth, D. Riesenberg and A. Plückthun. 1993. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Bio/Technology 11:1271-1277.
125. Parmley, S.F. and G.P. Smith. 1988. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 73:305-318.
126. Pedroso, I., A. Agraz, J. Brito, R. Páez, J.L. Segredo, J. García, M. Pérez, V. Lugo et al. 1997. Immunoaffinity purification of a particulate recombinant HBsAg using single-chain Fv antibody fragments. Minerva Biotecnologica 9:68-75.
127. Penichel, M.L., Y.S. Kang, W.M. Pardridge, S.L. Morrison and S.U. Shin. 1999. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163:4421-4426.
128. Persson, M.A.A., R.H. Caothien and D.R. Burton. 1991. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. USA 88:2432-2436.
129. Plückthun, A. 1991. Strategies for the expression of antibody fragments in Escherichia coli. Methods: A Companion to Methods Enzymol. 2:88-96.
130. Pollock, D.P., J.P. Kutzko, E. Birck-Wilson, J.L. Williams, Y. Echelard and H.M. Meade. 1999. Transgenic milk as a method for the production of recombinant antibodies. J. Immunol. Methods 231:147-157.
131. Porath, J. 1992. Immobilized metal ion affinity chromatography. Protein Expr. Purif. 5:263-281.
132. Present, D.H. 1999. Review article: the efficacy of infliximab in Crohn's disease - healing of fistulae. Aliment Pharmacol. Ther. 13:23-28.
133. Proba, K., L. Ge and A. Plückthun. 1995. Functional antibody single chain fragments from the cytoplasm of E. coli: influence of thioredoxin reductase (TrxB). Gene 159:203-207.
134. Queen, C. and H.E. Selick. 1996 (issued). Humanized immunoglobulins. US5530101.
135. Rebello, P.R., G. Hale, P.J. Friend, S.P. Cobbold and H. Waldmann. 1999. Antiglobulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation 68:1417-1420.
136. Reff, M.E. 1993. High-level production of recombinant immunoglobulins in mammalian cells. Curr. Opin. Biotechnol. 4:573-576.
137. Reichmann, L., M. Clark, H. Waldmann and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323-327.
138. Reiter, Y., U. Brinkmann, B. Lee and I. Pastan. 1996. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat. Biotechnol. 14:1239-1245.
139. Ridder, R., R. Schmitz, F. Legay and H. Gram. 1995. Generation of rabbit monoclonal antibody fragments from a combinatorial phage display library and their production in the yeast Pichia pastoris. Bio/Technology 13:255-260.
140. Riechmann, L., J. Foote and G. Winter. 1988. Expression of an antibody Fv fragment in myeloma cells. J. Mol. Biol. 203:825-828.
141. Riechmann L. and S. Muyldermans. 1999. Single domain antibodies: comparison of camel VH and camelised human VH domains. J. Immunol. Methods 231:25-38.
142. Romanos, M.A., C.A. Scorer and J.J. Clare. 1992. Foreign gene expression in yeast: a review. Yeast 8:423-488.
143. Roude, VV. 1997. From benchtop to bedside. Science 278:1036-1040.
144. Saez-Llorens, X., E. Castano, D. Null, J. Steichen, P.J. Sanchez, O. Ramilo, F.H. Top, Jr. and E. Connor. 1998. Safety and pharmacokinetics of an intramuscular humunized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronehopulmonary dysplasia. The MEDI-493 Study Group. Pediatr. Infect. Dis. J. 17:787-791.
145. Sanchez, L., M. Ayala, F. Freyre, I. Pedroso, H. Bell, V. Falcon and J.V. Gavilondo. 1999. High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen. J. Biotechnol. 72:13-20.
146. Saragovi, H.U., D. Fitzpatrick, A. Raktabutr, H. Nakanishi, M. Kahn and M. Greene. 1991. Design and sythesis of a mimetic from an antibody complementarity-determining region. Science 253:792-795.
147. Sblattero, D. and A. Bradbury. 2000. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat. Biotechnol. 18:75-80.
148. Schaffitzel, C., J. Hanes, L. Jermutus and A. Plückthun. 1999. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods 231:119-135.
149. Schultz, P.G. and R.A. Lerner. 1995. From molecular diversity to catalysis: lessons from the immune system. Science 269:1835-1842.
150. Sensel, M.G., M.J. Coloma, E.T. Harvill, S.U. Shin, R.I. Smith and S.L. Morrison. 1997. Engineering novel antibody molecules. Chem. Immunol. 65:129-158.
151. HCK protein in mouse myeloma cells. Nature 309:364-367.
152. Shield, C.F., R.J. Jacobs, S. Wyant and A. Das. 1996. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am. J. Kidney Dis. 27:855-864.
153. Skerra, A. and A. Plückthun. 1988. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240:1038-1041.
154. Skerra, A., I. Pfitzinger and A. Plückthun. 1991. The functional expression of antibody Fv fragments in Escherichia coli. improved vectors and a generally applicable purification technique. Bio/technology 9:273-277.
155. Slade, H.B. 1994. Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin. Diag. Lab. Immunol. 1:613-619.
156. Thompson, K.M. 1988. Human monoclonal antibodies. Immunol. Today 9:113-117.
157. H segments with different hypervariable loops. J. Mol. Biol. 227:776-798.
158. Vaughan, T.J., A.J. Williams, K. Pritchard, J.K. Osbourn, A.R. Pope, J.C. Earnshaw, J. McCafferty, R.A. Hodits, J. Wilton and K.S. Johnson. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol. 14:309-314.
159. Verhoeyen, M., C. Milstein and G. Winter. 1988. Reshaping human antibodies: grafting an anti-lysozyme activity. Science 239:1098-1104.
160. von Behring, E. and S. Kitasato. 1890. Ueber Zustandekommen der Diphtherie-Immunitat und der Tetanus-Immunitat bei Thieren. S. Dtsch. Med. Wochenschr. 16:1113-1116.
161. Waterhouse, P., A. Griffiths, K. Johnson and G. Winter. 1993. Combinatorial infection and in vivo recombination: a strategy for making large phage antibody repertoires. Nucleic Acids Res. 21:2265-2266.
162. Weiner, L.M. 1999. Monoclonal antibody therapy of cancer. Semin. Oncol. 26:43-51.
163. Weisman, L.E., D.F. Cruess and G.W. Fischer. 1994. Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr. Infect. Dis. J. 13:1122-1125.
164. Williams, W.V., T. Kieber-Emmons, J. Von-Feldt, M.I. Greene and D.B. Weiner. 1991 Design of bioactive peptides based on antibody hypervariable region structures. J. Biol. Chem. 266:5182-5190.
165. Winter, G. 1993 (issued). Recombinant altered antibodies and methods of making allered antibodies. US5225539.
166. Wood, C.R., M.A. Boss, J.H. Kenten, J.E. Calvert and N.A. Roberts. 1985. The synthesis and in vivo assembly of functional antibodies in yeast. Nature 314:446-447.
167. Woodle, E.S., D. Xu, R.A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L.K. Jollife et al. 1999. Phase I trial of a humanized. Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608-616.
168. Xiong, S., M. Gerloni and M. Zanetti. 1997. Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. Nat. Biotechnol. 15:882-886.
169. Yang, X.D., X.C. Jia, J.R. Corvalan, P. Wang, C.G. Davis and A. Jacobovits. 1999. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59:1236-1243.